For questions, or to speak with someone directly, please call:
1-888-824-0200
To request an appointment, please use our secure online form. A representative will contact you within one to two business days to help you schedule an appointment.
Schedule an Appointment on Zocdoc
Current patients may also use MyChart to request an appointment.
The patient portal is not for medical emergencies. If you have a medical emergency, call 911.
For help with MyChart, call us at 1-844-442-4278.
For help with Ingalls Care Connection, call us at 1-708-915-4357 or email portalsupport@ingalls.org.
Find a Clinical Trial
This is a Phase 3, randomized, double-blind, placebo-controlled multicenter global study designed to compare the efficacy and safety of tislelizumab in combination with concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy versus cCRT alone, and tislelizumab...
Interventional / Recruiting / NCT03745222
This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small Cell Lung Cancer naïve to checkpoint inhibitor therapy, Non-Small Cell Lung Cancer who have...
Interventional / Recruiting / NCT03583086
This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other...
Interventional / Recruiting / NCT03375320
This study will examine the safety profile of SEA-CD40 given alone and in combination with pembrolizumab. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find...
Interventional / Recruiting / NCT02376699
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with advanced non-small cell lung cancer and metastatic triple-negative breast cancer.
Interventional / Recruiting / NCT03674827
The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression.
Interventional / Recruiting / NCT03631706
This expanded access study has being designed following a demand from the FDA, given the increase in the number of request for single patient INDs for lorlatinib
Expanded Access / Recruiting / NCT03178071
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with a programmed cell death protein 1 (PD-1) inhibitor.
Interventional / Recruiting / NCT03667716
The purpose of this research study is to test a touchscreen computer program, which allows patients to see information on a computer screen regarding cancer care, and specifically clinical trials. The purpose of this research is to help the investigators...
Observational / Recruiting / NCT02020252
The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 and Phase 2.
Interventional / Recruiting / NCT02178722
